Regulon: R-2989
Regulons are regulatory units consisting of a coherently expressed set of genes and the associated regulator(s) whose binding site(s) they share.
Regulon Summary
Regulon summary table displays all associated information related to the specific regulon including the number of genes in the regulon, Hazard ratio, its Regulator, the Transcriptional Program that includes the regulon, Drugs that are associated with members of the regulon, together with mechanism of action and class, and enriched hallmarks of cancer if any.
| Genes | Cox Hazard Ratio | Regulators | Causal Flows | Transcriptional Programs | Hallmarks |
|---|---|---|---|---|---|
| 12 | 2.28575 | 1 | 2 | Pr-17 |           |
Regulon Genes
List of genes that are included in the regulon. These genes have similar expression profiles in subset of patients and they share common binding motif for the Regulator of the regulon. Clicking on the gene name will take you to the gene specific page with more details. Please wait while information is collated from several resources after you click.
Regulon Drugs
| Name | Approved Symbol | Type | Action Type | Mechanism of Action | Max Trial Phase | Max GBM Phase |
|---|---|---|---|---|---|---|
| SAVOLITINIB | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 3 | 0 |
| TELISOTUZUMAB VEDOTIN | MET | Antibody | BINDING AGENT | Hepatocyte growth factor receptor binding agent | 3 | 0 |
| AMUVATINIB | FLT3 | Small molecule | INHIBITOR | Platelet-derived growth factor receptor alpha inhibitor | 2 | 0 |
| CABOZANTINIB | MET | Small molecule | INHIBITOR | Vascular endothelial growth factor receptor 2 inhibitor | 4 | 2 |
| ALTIRATINIB | TEK | Small molecule | INHIBITOR | Neurotrophic tyrosine kinase receptor inhibitor | 1 | 0 |
| SGX-523 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 1 | 0 |
| TEREVALEFIM | MET | Small molecule | AGONIST | Hepatocyte growth factor receptor agonist | 3 | 0 |
| TEPOTINIB HYDROCHLORIDE | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 4 | 0 |
| FORETINIB | TEK | Small molecule | INHIBITOR | Tyrosine-protein kinase TIE-2 inhibitor | 2 | 0 |
| ONARTUZUMAB | MET | Antibody | ANTAGONIST | Hepatocyte growth factor receptor antagonist | 3 | 2 |
| SAR-125844 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 2 | 0 |
| AMG-208 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 2 | 0 |
| MK-8033 | MET | Small molecule | INHIBITOR | Macrophage-stimulating protein receptor inhibitor | 1 | 0 |
| AMG-337 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 2 | 0 |
| CAPMATINIB HYDROCHLORIDE | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 4 | 0 |
| AMIVANTAMAB | MET | Antibody | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 4 | 0 |
| MK-2461 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 2 | 0 |
| MERESTINIB | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 2 | 0 |
| BMS-777607 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 2 | 0 |
| CAPMATINIB | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 4 | 1 |
| JNJ-38877605 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 1 | 0 |
| GLESATINIB | KDR | Small molecule | INHIBITOR | Tyrosine-protein kinase TIE-2 inhibitor | 2 | 0 |
| BMS-817378 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 1 | 0 |
| CABOZANTINIB S-MALATE | MET | Small molecule | INHIBITOR | Vascular endothelial growth factor receptor 2 inhibitor | 4 | 2 |
| CRIZOTINIB | ALK | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 4 | 1 |
| EMD-1204831 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 1 | 0 |
| TIVANTINIB | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 3 | 0 |
| TELISOTUZUMAB | MET | Antibody | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 1 | 0 |
| TEPOTINIB | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 4 | 0 |
| EMIBETUZUMAB | MET | Antibody | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 2 | 0 |
| BPI-9016 | AXL | Small molecule | INHIBITOR | Tyrosine-protein kinase receptor UFO inhibitor | 1 | 0 |
| PF-04217903 | MET | Small molecule | INHIBITOR | Hepatocyte growth factor receptor inhibitor | 1 | 0 |
| GOLVATINIB | KDR | Small molecule | INHIBITOR | Vascular endothelial growth factor receptor 2 inhibitor | 2 | 0 |
Causal Flows
Causal Flows are statistically significant links between putative causal events (somatic mutations, copy number variations, chromosomal translocations, etc.) and the activity levels of regulators and regulons. In the causal flow a mutation may causally activates or deactivates a downstream regulator which then might up- or down-regulates a regulon that contains genes with similar expression profiles and binding sites.